热门资讯> 正文

CRISPR Therapeutics申请6亿美元股票发行

2025-10-16 17:49

CRISPR Therapeutics (NASDAQ:CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common shares through Jefferies LLC, acting as its sales agent.
The sale will take place from time to time at the company’s discretion under its existing open market sale agreement with Jefferies, first established in August 2019, and will be conducted under the firm’s shelf registration statement filed in August 2024.

More on CRISPR Therapeutics

Crispr: Investors Waiting Patiently For In-Vivo
Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track
CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Cathie Wood's Ark Invest weekly recap: lifts stake in Bullish and Brera, trims Roku and Tempus AI
CRISPR Therapeutics wins new Overweight rating at J.P. Morgan on pipeline prospects

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。